Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 3/20 | 0.67 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.67 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.67 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.67 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.59 |
| ▸ | CA12 | O43570 | 1/20 | 0.58 |
| ▸ | CA1 | P00915 | 1/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.58 |
| ▸ | CA9 | Q16790 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3549311 | 0.81 | CA12 (0.59) | CA12CA1CA2CA9MAPT | |
| SCHEMBL3765919 | 0.81 | CA12 (0.59) | HDAC1HDAC7HDAC8HDAC6CA12 | |
| SCHEMBL5549558 | 0.81 | CA12 (0.59) | CA12CA1CA2CA9MAPT | |
| SCHEMBL8930990 | 0.80 | TRPV1 (0.47) | HDAC1HDAC7HDAC8HDAC6TRPV1 | |
| SCHEMBL13002990 | 0.79 | MAPT (0.59) | HDAC1HDAC7HDAC8HDAC6CA12 | |
| SCHEMBL6521536 | 0.79 | CA12 (0.58) | HDAC1HDAC7HDAC8HDAC6CA12 | |
| SCHEMBL490629 | 0.79 | CA12 (0.58) | HDAC1HDAC7HDAC8HDAC6CA12 | |
| SCHEMBL20870704 | 0.79 | EPHX2 (0.70) | TRPV1CA12CA1CA2CA9 | |
| SCHEMBL5550330 | 0.79 | HDAC1 (0.67) | HDAC1HDAC7HDAC8HDAC6CA12 | |
| SCHEMBL15270323 | 0.79 | L3MBTL1 (0.79) | HDAC1HDAC7HDAC8HDAC6TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8450490-B2 | Bi-functional pyrazolopyridine compounds | GILEAD SCIENCES, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| EP-2569285-A1 | BIFUNCTIONAL QUINOLINE DERIVATIVES | Gilead Sciences, Inc. (US) | 2013-03-20 | — | — | EP | disclosed |
| US-8394829-B2 | Bi-functional quinoline analogs | GILEAD SCIENCES, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-8394829-B2 | Bi-functional quinoline analogs | GILEAD SCIENCES, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-8367829-B2 | Bi-functional pyrazolopyridine compounds | GILEAD SCIENCES, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20130018050-A1 | BI-FUNCTIONAL PYRAZOLOPYRIDINE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-01-17 | — | — | US | disclosed |
| US-20130012504-A1 | BI-FUNCTIONAL QUINOLINE ANALOGS | GILEAD SCIENCES, INC (US) | 2013-01-10 | — | — | US | disclosed |
| US-20130012504-A1 | BI-FUNCTIONAL QUINOLINE ANALOGS | GILEAD SCIENCES, INC (US) | 2013-01-10 | — | — | US | disclosed |
| WO-2011143105-A1 | BIFUNCTIONAL QUINOLINE DERIVATIVES | GILEAD SCIENCES, INC. (US) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011143105-A1 | BIFUNCTIONAL QUINOLINE DERIVATIVES | GILEAD SCIENCES, INC. (US) | 2011-11-17 | — | — | WO | disclosed |
| EP-1501798-A2 | SULFONYLAMINOVALEROLAC TAMS AND DERIVATIVES THEREOF AS FACTOR Xa INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-02-02 | — | — | EP | disclosed |
| WO-2004041776-A2 | SULFONYLAMINOVALEROLAC TAMS AND DERIVATIVES THEREOF AS FACTOR Xa INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-05-21 | — | — | WO | disclosed |
| US-20040006062-A1 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-01-08 | — | — | US | disclosed |
| US-20030153027-A1 | Reagents for the quantitation of active oxygen | SEKISUI MEDICAL CO., LTD. (JP) | 2003-08-14 | — | — | US | disclosed |
| EP-1260508-A1 | REAGENTS FOR THE QUANTITATION OF ACTIVE OXYGEN | DAIICHI PURE CHEMICALS CO., LTD. (JP) | 2002-11-27 | — | — | EP | disclosed |
| US-5691349-A | ANTICHOLESTEROL AGENTS; ATHEROSCLEROSIS | ZENECA LIMITED (GB) | 1997-11-25 | — | — | US | disclosed |
| EP-0654032-B1 | QUINUCLIDINE DERIVATIVES AS SQUALENE SYNTHASE INHIBITORS | ZENECA LTD (GB) | 1997-10-15 | — | — | EP | disclosed |
| US-5644024-A | MIMICS OF PEPTIDE DOMAINS, SEQUENCE DETERMINATION, DRUGS | HOFFMANN-LA ROCHE INC. (US) | 1997-07-01 | — | — | US | disclosed |
| EP-0654032-A1 | QUINUCLIDINE DERIVATIVES AS SQUALENE SYNTHASE INHIBITORS. | ZENECA LTD (GB) | 1995-05-24 | — | — | EP | disclosed |
| WO-1994003451-A1 | QUINUCLIDINE DERIVATIVES AS SQUALENE SYNTHASE INHIBITORS | ZENECA LIMITED (GB) | 1994-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012504-A1 | BI-FUNCTIONAL QUINOLINE ANALOGS | BDKRB2, BDKRB1, HRH2 | HDAC1 914/4885HDAC7 1035/4885HDAC8 2580/4885 |
| US-20130018050-A1 | BI-FUNCTIONAL PYRAZOLOPYRIDINE COMPOUNDS | BDKRB2, BDKRB1, P2RX7 | HDAC1 876/4885HDAC7 1372/4885HDAC8 2511/4885 |
| US-20040006062-A1 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | TFPI, SPINT2, PRSS1 | HDAC1 175/4885HDAC7 609/4885HDAC8 585/4885 |
| US-20030153027-A1 | Reagents for the quantitation of active oxygen | CBR1, LPO, CBR3 | HDAC1 1578/4885HDAC7 1662/4885HDAC8 3243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.